Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-963-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
The No Observed Adverse Effect Level (NOAEL) for general systemic toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 322 mg/kg bw/day in males and 331 mg/kg bw/day in females. It was also concluded the NOAEL for reproductive/developmental toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 342 mg/kg bw/day during gestation and 731 mg/kg bw/day during lactation. The mean of the mean achieved doses for males and females toxicity and fertility, obtained during the OECD 422 study corresponds to 326 mg/kg bw/day.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 27 February to 12 July, 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study performed according to OECD test guideline No. 422 and in compliance with GLP.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Inspected on 2019-04-02 / Signed on 2019-08-01
- Limit test:
- no
- Justification for study design:
- - Basis for dose level selection: The target dietary concentrations selected for investigation in this OECD 422 combined repeated dose toxicity study and reproductive/developmental toxicity screening study (0, 1500, 3500 and 7500 ppm) were chosen in conjunction with the Sponsor and were based on the results of a 14-day preliminary study conducted at these laboratories (Envigo Study No. HX59HH).
- Route of administration: The dietary route of administration was chosen to simulate the conditions of potential human exposure.
- Animal model: The rat was chosen as the test species because of the requirement for a rodent species by regulatory agencies. The Crl:CD(SD) was used because of the historical control data available at this laboratory. - Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Details on species / strain selection:
- The rat was chosen as the test species because of the requirement for a rodent species by regulatory agencies. The Crl:CD(SD) was used because of the historical control data available at this laboratory.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd.
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: Males 69 to 75 days old. Females: 83 to 89 days old.
- Weight at study initiation: Males: 322-400 g; Females: 238 to 311 g
- Housing: Cages comprised of a polycarbonate body with a stainless steel mesh lid; changed at appropriate intervals. Solid (polycarbonate) bottom cages were used during the acclimatization and pre-treatment periods.
- Number of animals per cage:
* Pre-pairing, toxicity phase females and recovery animals: up to four animals of one sex
* Pairing: one male and one female
* Males after mating: up to four animals
* Gestation: one female
* Lactation: one female + litter
- Acclimatization and pre-treatment: Males: six days before commencement of treatment.Females: 20 days before commencement of treatment.
- Diet: SDS VRF1 Certified powdered diet, ad libitum (removed overnight before blood sampling for hematology and blood chemistry investigations and during urine collection)
- Water: Potable water from the public supply via polycarbonate bottles with sipper tubes, ad libitum (removed overnight during urine collection)
- Acclimation period:
ENVIRONMENTAL CONDITIONS
- Temperature: 20-24 °C
- Humidity: 40-70 %
- Air changes: Filtered fresh air which was passed to atmosphere and not recirculated.
- Photoperiod: Artificial lighting, 12 h light : 12 h dark
- Environmental Enrichment
Aspen chew block: A soft white untreated wood block; provided to each cage throughout the study (except during pairing and lactation) and replaced when necessary.
Plastic shelter: Provided to each cage throughout the study (except during pairing and lactation) and replaced at the same time as the cages.
IN-LIFE DATES: from 13 March to 12 July 2019. - Route of administration:
- oral: feed
- Vehicle:
- other: feed
- Details on exposure:
- DIET PREPARATION
- Diet: SDS VRF1 Certified powdered diet
- Correction factor: A correction factor was not required.
- Stabilizer: Corn oil (test material to corn oil ratio 5:1).
- Method of preparation: The test substance was incorporated into the diet to provide the required concentrations by initial preparation of a premix. The test item was melted at 70°C before weighing. On each occasion of the preparation of the premix the required amount of test item and solvent (acetone) were weighed out and magnetically stirred until the test item was fully dispersed. The mixture was added to the appropriate amount of plain diet. A further amount (approximately 100 g) of plain diet was used to clean the weighing container and then added to the mixture. This mixture was stirred well, then left for the solvent (acetone) to evaporate for at least 45 minutes while stirred frequently, until a constant weight was achieved and at least 90% of the initial weight of added solvent was removed. The required amount of corn oil was added to the mixture. Additional diet was used to rinse the corn oil weighing container which was then added to the mixture. This was ground using a mechanical grinder then made up to the correct weight with plain diet. The formulation was transferred to a plastic container and mixed using a Turbula mixer for 100 cycles at 16 rpm to ensure all the
test item was dispersed in the diet. Aliquots of the premix were then diluted with further quantities of plain diet to produce the required dietary concentrations. Each batch of treated diet was mixed for a further 100 cycles in a Turbula mixer.
- Storage of formulation: Frozen (-10 to -30°C). - Details on mating procedure:
- - Animals: Toxicity phase and Recovery phase males with Reproductive phase females (Toxicity and Recovery phase females were not paired for mating).
- M/F ratio per cage: 1:1 from within the same treatment groups
- Pairing commenced: After a minimum of three weeks of treatment.
- Length of cohabitation: Up to 2 weeks
- Proof of pregnancy: Presence of sperm within the vaginal smear and/or ejected copulation plugs referred to as Day 0 of gestation.
- Male/female separation: Day when mating evidence was detected.
- Pre-coital interval: Calculated for each female as the time between first pairing and evidence of mating. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Stability and homogeneity: The homogeneity and stability of Labdanum Gum in the concentration range of 800 ppm to 20000 ppm in SDS VRF1 diet was confirmed as part of another study, Covance study number GS09VH.
- Achieved concentration: Samples of each formulation prepared for administration were analyzed for achieved concentration of the test item. - Duration of treatment / exposure:
- Reproductive phase females: Three weeks before pairing, then throughout pairing and gestation until Day 12 of lactation (necropsy on Day 13 of lactation (the diet was available to the animals until the morning of necropsy)).
Toxicity phase males: Three weeks before pairing up to necropsy after minimum of six weeks.
Toxicity phase females: At least six weeks.
Recovery phase males: Three weeks before pairing up to necropsy after minimum of six weeks followed by a minimum 14-day recovery.
Recovery phase females: At least six weeks followed by a minimum 14-day recovery.
Animals of the F1 generation received no direct administration of test item; any exposure was in utero or via the milk. - Frequency of treatment:
- Continuously
- Dose / conc.:
- 0 ppm
- Remarks:
- Control group (Basal diet + corn oil) / Group 1
- Dose / conc.:
- 1 500 ppm
- Remarks:
- Group 2 (Low dose)
- Dose / conc.:
- 3 500 ppm
- Remarks:
- Group 3 (mid dose)
- Dose / conc.:
- 7 500 ppm
- Remarks:
- Group 4 (High dose)
- No. of animals per sex per dose:
- Reproductive phase females: 10 animals/dose
Toxicity phase females: 5 females/dose in all groups; 5 males/dose in control and high dose groups; 10 males/dose in low and mid dose groups
Recovery phase animals: 5 animals/sex/dose in control and high dose groups - Control animals:
- yes, plain diet
- Details on study design:
- The target dietary concentrations selected for investigation in this OECD 422 combined repeated dose toxicity study and reproductive/developmental toxicity screening study (0, 1500, 3500 and 7500 ppm) were chosen in conjunction with the Sponsor and were based on the results of a 14-day preliminary study conducted at these laboratories (Envigo Study No. HX59HH).
- Rationale for animal assignment: On arrival and non-selective allocation to cages.
Estrous cycles were evaluated prior to treatment. After 14 days evaluation, animals that failed to exhibit typical 4-5 day cycles were not allocated to the reproductive phase of the study.
On Day 1 of study all animals were weighed and body weights were reviewed before feeding of the treated diets by Study Management to ensure variations in body weight of animals did not exceed ±20% of the mean for each sex. Groups were adjusted to reduce inter-/intra-group variation.
- Other: Each adult animal was assigned a number and identified uniquely within the study by a tail tattoo before Day 1 of treatment. The offspring were numbered individually within each litter on Day 1 of age, using a toe tattoo.
Animal Replacement: Before the commencement of treatment, study allocation was revised to reduce inter/intra group body weight variation by replacement of animals with spares and moving animals within groups. Any individuals rejected during the acclimatization period were replaced with spare animals of suitable weight from the same batch.
Replacement before allocation: Abnormal estrus cycle - 11 females; Body weight range extremes - 3 males - Positive control:
- Not applicable
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment. Cages were inspected daily for evidence of animal ill-health amongst the occupant(s). During the acclimatization period, observations of the animals and their cages were recorded at least once per day.
A viability check was performed near the start and end of each working day. Animals were killed for reasons of animal welfare where necessary.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Before treatment commenced, during each week of treatment and recovery, on Days 0, 6, 13 and 20 after mating and on Days 1, 6 and 12 of lactation, detailed physical examination and arena observations were performed on each animal. On each occasion, the examinations were performed at approximately the same time of day (before feeding of the treated diets on Day 1).
BODY WEIGHT: Yes
- Time schedule for examinations:
F0 Toxicity and Recovery phase males and females: Weekly during acclimatization; Before feeding of the treated diets on the day that treatment commenced (Day 1) and weekly thereafter, including the recovery phase. On Day 5 of recovery the animals were fed diets prepared for the females in the lactation phase in error (recovery control animals received control diet with the corn oil stabiliser, and recovery animals in Group 4 received treated diet (8000 ppm); On the day of necropsy.
F0 Reproductive phase females: Weekly during acclimatization; Before feeding of the treated diets on the day that treatment commenced (Day 1) and weekly before pairing; Days 0, 7, 14 and 20 after mating; Day 1, 4, 7 and 13 of lactation; On the day of necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- The weight of food supplied to each cage, that remaining and an estimate of any spilled was recorded as follows:
F0 animals: Daily, including the recovery phase. On Day 5 of recovery the animals were fed diets prepared for the females in the lactation phase in error (recovery control animals received control diet with the corn oil stabiliser, and recovery animals in Group 4 received treated diet (8000 ppm). Food consumption was not recorded for Toxicity phase males and Reproductive phase females during the period when paired for mating (Week 3), but recommenced for males in Week 4. Food consumption was recorded continuously for Toxicity and Recovery phase females. For Reproductive phase females after mating food consumption was performed daily throughout gestation and lactation (until Day 12).
From these records the mean daily consumption per animal (g/animal/day) was calculated for each phase.
OTHER:
NEUROBEHAVIOURAL EXAMINATION:
- Time schedule:
Sensory reactivity and grip strength: Sensory reactivity and grip strength assessments were performed on all recovery animals in Groups 1 and 4 and on the lowest numbered toxicity phase males and females in Groups 2 and 3 during Week 6 of treatment.
Motor activity: During Week 6 of treatment, the motor activity of all recovery animals in Groups 1 and 4 and on the lowest numbered toxicity phase males and females in Groups 2 and 3 was measured.
OPHTHALMOLOGY
- Time schedule:
Pre-treatment: All Toxicity and Recovery phase animals and spare animals; Week 6: All Toxicity phase females and the first five Toxicity phase males of Groups 1 and 4
The eyes of the animals were examined by means of a binocular indirect ophthalmoscope. Prior to each examination, the pupils of each animal were dilated using tropicamide ophthalmic solution (Mydriacyl). The adnexae, conjunctiva, cornea, sclera, anterior chamber, iris (pupil dilated), lens, vitreous and fundus were examined.
HAEMATOLOGY AND CLINICAL CHEMISTRY:
- Time schedule for collection of blood:
Week 6: Five lowest numbered surviving Toxicity phase males and females in each group; Recovery: All male Recovery animals
- Animals fasted: Yes, blood samples were collected after overnight withdrawal of food; animals were also deprived of water overnight but had access to water for a minimum period of one hour prior to the commencement of blood sampling procedures.
- Animals were held under light general anaesthesia induced by isoflurane. Blood samples were withdrawn from the sublingual vein. Sampling was performed on the morning after overnight collection of urine.
- Haematology parameters: Haematocrit, Haemoglobin concentration, Erythrocyte count (RBC), Absolute reticulocyte count, Mean cell haemoglobin, Mean cell haemoglobin concentration, Mean cell volume, Red cell distribution width, Total leucocyte count, Differential leucocyte count: Neutrophils, Lymphocytes, Eosinophils, Basophils, Monocytes, Large unstained cells, Platelet count, Prothrombin time and Activated partial thromboplastin time.
- Blood Chemistry parameters: Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-glutamyl transpeptidase (gGT), Total bilirubin, Bile acids, Urea, Creatinine, Glucose, Total cholesterol, Triglycerides, Sodium (Na), Potassium (K), Chloride (Cl), Calcium (Ca), Inorganic phosphorus, Total protein, Albumin and Albumin/globulin ratio (A/G Ratio).
Urinalysis
- Time schedule for collection of urine:
Week 6: Five lowest numbered surviving Toxicity phase males and females in each group; Recovery: All Recovery animals
Metabolism cages used for collection of urine: Yes; animals were placed in an individual metabolism cage, without access to food or water. Urine samples were collected overnight.
- Parameters:
Using manual methods: Clarity and Color/Appearance (App) - by visual assessment; Volume (Vol) - using a measuring cylinder; pH - using a pH meter; Specific gravity (SG) - by direct refractometry using a SG meter
Using Multistix reagent strips interpreted using the Clinitek®500 instrument: Ketones, Bile pigments, Urobilinogen, Blood pigments
Using a Roche P Modular Analyzer: Protein, Creatinine, Glucose, Sodium, Potassium, Chloride
A microscopic examination of the urine sediment was performed: Epithelial cells, Leucocytes (WBC), Erythrocytes (RBC), Casts and Other abnormal components (A)
The slide was also examined for abnormalities in spermatozoa and crystals.
Thyroid Hormone Analysis
- Time schedule for examination
At termination: F0 males, All F0 Reproductive phase females
Day 4 of age - F1 offspring, two females per litter (where possible) - no pups were eliminated when litter size dropped below ten/litter
- one for T4 (serum)#
- one for TSH (plasma - optional analysis)
# priority given to serum sample
Day 13 of age: F1 offspring, two males and two females per litter (where possible)
- two for T4 (serum): where possible one male and one female#
- two for TSH (plasma): where possible one male and one female
# priority given to serum sample
PARTURITION OBSERVATIONS AND GESTATION LENGTH:
- Duration of gestation: Time elapsing between the detection of mating and commencement of parturition.
- Parturition observations: From Day 20 after mating, females were inspected three times daily for evidence of parturition. The progress and completion of parturition was monitored, numbers of live and dead offspring were recorded and any difficulties observed were recorded. - Oestrous cyclicity (parental animals):
- Estrous Cycle
Wet smears:
Using pipette lavage during the following phases:
- For 14 days before treatment (all females including spares); animals that failed to exhibit 4-5 day cycles were not allocated to the Reproductive phase of the study.
- After pairing until mating.
- For four days before scheduled termination (all Reproductive phase, Toxicity phase and Recovery phase females).
Dry smears:
Reproductive phase females: from beginning of treatment until animals were paired for mating, using cotton swabs (approximately three weeks). - Litter observations:
- Clinical observations: Examined at approximately 24 h after birth (Day 1 of age) and then daily thereafter for evidence of ill health or reaction to maternal treatment; these were on an individual offspring basis or for the litter as a whole, as appropriate.
Litter size: Daily records were maintained of mortality and consequent changes in litter size from Days 1-13 of age.
Sex ratio of each litter Recorded on Days 1, 4, 7 and 13 of age.
Individual offspring body weights: Days 1, 4, 7 and 13 of age.
Ano-genital distance: Day 1 - all F1 offspring.
Nipple/areolae count: Day 13 of age - male offspring. - Postmortem examinations (parental animals):
- SACRIFICE
Time of necropsy
Toxicity phase:
F0 males and females: After Week 6 investigations were completed.
Reproductive phase females:
F0 females failing to produce a viable litter: Day 25 after mating.
F0 females: Day 13 of lactation.
Recovery phase
F0 Males and females: After at least 14 days without treatment.
- Method of sacrifice: All adult animals were killed by Carbon dioxide asphyxiation with subsequent exsanguination. (No animal was exposed to carbon dioxide until after completion of thyroid hormone assays).
GROSS NECROPSY
- Necropsy: All adult animals were subject to a detailed necropsy. After a review of the history of each animal, a full macroscopic examination of the tissues was performed. All external features and orifices were examined visually. Any abnormality in the appearance or size of any organ and tissue (external and cut surface) was recorded and the required tissue samples preserved in appropriate fixative.
Main phase females
The following were recorded:
Each uterine horn: Number of implantation sites was counted and confirmed.
ORGAN WEIGHTS
- For bilateral organs, left and right organs were weighed together. Requisite organs were weighed for animals killed at scheduled intervals.
HISTOPATHOLOGY
- Fixation: Tissues were routinely preserved in 10% Neutral Buffered Formalin with the exception of those detailed below:
Testes: Initially in modified Davidson’s fluid; Eyes: In Davidson’s fluid.
- Histology
Processing: Tissue samples were dehydrated, embedded in paraffin wax and sectioned at a nominal four to five micron thickness. For bilateral organs, sections of both organs were prepared. A single section was prepared from each of the remaining tissues required.
Full List: All F0 animals killed or dying prematurely; Toxicity phase males and females in Groups 1 and 4 at scheduled termination.
Abnormalities: All remaining adult animals.
Routine staining: Sections were stained with hematoxylin and eosin; in addition samples of the testes were stained using a standard periodic acid/Schiff (PAS) method. - Postmortem examinations (offspring):
- SACRIFICE
Time of necropsy:
Selected offspring for Day 4 thyroid hormone analysis - Day 4 of age.
Scheduled kill - Day 13 of age.
Method of sacrifice:
- Offspring- selected for thyroid hormone sampling on Day 4 or Day 13 of age: Decapitation
- Offspring - not selected for thyroid hormone sampling: Intraperitoneal injection of sodium pentobarbitone.
GROSS NECROPSY
Where possible, a fresh macroscopic examination (external and internal) with an assessment of stomach for milk content was performed. Abnormal tissues retained.
- F1 offspring on Day 4 of age:
Blood sampling required
Externally normal offspring discarded without examination.
Externally abnormal offspring identified on despatch to necropsy, examined externally, and retained pending possible future examination.
- F1 offspring on Day 13 of age
Blood sampling required
All animals (but not including those selected for thyroid hormone analysis) were subject to an external macroscopic examination; particular attention was paid to the external genitalia. Thyroid glands were preserved from one male and one female in each litter.
Animals selected for thyroid hormone analysis: externally normal offspring discarded without examination; externally abnormal offspring examined. - Statistics:
- See "Any other information on materials and methods incl. tables"
- Reproductive indices:
- Mating Performance and Fertility:
- Percentage mating = (Number animals mating / Animals paired) x 100
- Conception rate (%) = (Number animals achieving pregnancy / Animals mated) x 100
- Fertility index (%) = (Number animals achieving pregnancy / Animals pairing) x 100
Gestation Length and Index: Gestation length was calculated as the number of gestation days up to and including the day on which offspring were first observed, with Day 1 = day of mating for calculation purposes. Where parturition had started overnight, this value was adjusted by subtracting half of one day.
Gestation index was calculated for each group as:
- Gestation index (%) = (Number of live litters born / Number pregnant ) x 100 - Offspring viability indices:
- Survival indices:
- Post-implantation survival index (%) = (Total number of offspring born / Total number of uterine implantation sites) x 100
- Live birth index (%) = (Number of live offspring on Day 1 after littering / Total number of offspring born) x 100
- Viability index (%) = (Number of live offspring on Day 4 (before blood sampling) / Number live offspring on Day 1 after littering) x 100
- Lactation index (%) = (Number of live offspring on Day 13 of lactation / Number live offspring on Day 4 (after blood sampling)) x 100
Sex ratio: The percentage of male offspring in each litter was calculated at Day 1, and for live offspring on Days 1, 4 and 13 of age.
- Percentage males = (Number of males in litter / Total number of offspring in litter) x 100 - Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical signs observed during the treatment period for Toxicity and Recovery phase animals or for Reproductive phase females prior to pairing, during gestation or during lactation that were considered related to dietary administration of Labdanum Gum. There were no signs observed during the recovery period that were considered to be associated with previous treatment with Labdanum Gum.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One male that received 1500 ppm (No. 7) was killed for welfare reasons on Day 29 of study due to a damaged right eye. Macroscopic examination revealed a protruding and abnormal dark coloured right eye. This death was considered not to be related to treatment with Labdanum Gum.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- During the first week of treatment there was an initial slight reduction in group mean body weight gain for Toxicity and Recovery phase males that received 3500 or 7500 ppm compared to Control. Overall group mean body weight gains for the treatment period (Days 1 to 43) were slightly lower than Control for all groups of treated males (97%, 83% and 93% of Control at 1500, 3500 and 7500 ppm respectively), however, no dose-response and no statistical significance were apparent. There was an initial group mean body weight loss, between Days 1 to 4 of treatment, for all groups of treated females, this minor loss was greatest at 7500 ppm. Thereafter, group mean body weight gain was observed for all groups of treated females, with the exception of Days 29 to 36 where a group mean body weight loss was apparent for females that received 1500 or 3500 ppm and weight gain was low at 7500 ppm. The overall group mean body weight gains (Days 1 to 43) for Toxicity and Recovery phase females treated at 3500 or7500 ppm were statistically significantly lower than Control (57% and 47% of Control at 3500 and 7500 ppm respectively).
During gestation, the group mean body weight gain for all groups of treated Reproductive phase females was slightly higher than Control (114%, 111% and 106% of Control at 1500, 3500 and 7500 ppm respectively). Overall body weight gain throughout lactation (Days 1 to 13) was slightly lower than Control for females that received 1500 or 7500 ppm and comparable to Control for females that received 3500 ppm (81%, 107% and 78% of Control at 1500, 3500 and 7500 ppm respectively), although statistically significant lower values than Control were observed in all treated groups between Days 7-13 (30%, 45% and 70% of Control at 1500, 3500 and 7500 ppm respectively).
During the recovery phase (R1 to R15), group mean body weight gain for males that previously received 7500 ppm was slightly lower than Control (80% of Control). Group mean body weight gain during the recovery phase for females that previously received 7500 ppm was much higher than Control although not statistically significant (2000% of Control). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The overall food intake of all groups of treated Toxicity and Recovery phase males was generally marginally lower than Control throughout the first three weeks of treatment (Days 1 to 22).
There was an initial statistically significant reduction in food intake, between Days 1 to 5 and 6-7, for females that received 7500 ppm following the commencement of treatment. Thereafter, the food intake of females that received 7500 ppm remained marginally lower than Control. The food intake of females that received 1500 or 3500 ppm was generally marginally lower than or comparable to Control throughout the treatment period.
The food intake during early gestation (Days 0 to 8) for Reproductive phase females that received 7500 ppm was marginally lower than Control, with a statistical significance on Days 0-1 (78% of Control), but comparable to Control thereafter. The food intake during gestation for Reproductive phase females that received 1500 or 3500 ppm was comparable to Control.
The food intake during lactation (Day 1 to 13) for Reproductive phase females that received 7500 ppm was generally marginally lower than Control. The food intake during lactation for Reproductive phase females that received 1500 or 3500 ppm was generally slightly higher than Control.
The food intake during recovery for males and females that had previously received 7500 ppm was comparable to Control. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No effects of treatment were observed during ophthalmic examination in Week 6 of treatment for males and female animals treated at all dose levels.
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Haematology investigations for Toxicity phase animals during Week 6 of treatment with Labdanum Gum revealed no treatment related changes in either sex.
Activated partial thromboplastin time was statistically significantly higher than Control for males that received 3500 ppm, however, a dose response was not apparent. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Blood chemistry investigations during Week 6 of treatment revealed that creatinine levels for all groups of treated males were statistically significantly higher than Control but within the HCD range. Following a two-week recovery period, creatinine levels for males that had previously received 7500 ppm were comparable to Control.
During Week 6, a statistically significant decrease in urea concentration was apparent in females that received 7500 ppm but the value was within the HCD range. Following a two-week recovery period, urea concentration in females that had previously received 7500 ppm was comparable to Control.
During Week 6, a statistically significant increase in phosphorus levels was apparent amongst males and females that received 7500 ppm but all values were within the HCD range. Following a two-week recovery period, phosphorus levels in males and females that had previously received 7500 ppm were comparable to Control.
During Week 6, globulin levels for females that received 7500 ppm were statistically significantly higher than Control and slightly outside of the HCD range. Following a
two-week recovery period, globulin levels in females that had previously received 7500 ppm were comparable to Control. All other differences from Control, including those that attained statistical significance, were generally small, confined to one sex, or the magnitudes were not dose-relatded and,consequently, were considered to represent normal biological variation. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Total creatinine output was higher than Control for males treated at 3500 or 7500 ppm, however, all values were within the HCD range and no such trend was apparent in the females. Sodium concentration was higher than Control for all groups of treated females, however, all values were within the HCD range and no such trend was apparent in the males.
All other differences from Control were generally small, confined to one sex, or the magnitudes were not dose-related and, consequently, were considered to represent normal biological variation. - Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Sensory Reactivity Observations and Grip Strength:
No treatment-related effects were observed for sensory reactivity and grip strength assessment during Week 6 of treatment for males and females at all dose levels.
Motor Activity:
Motor activity assessment of males and females during Week 6 of treatment revealed no treatment-related effects at any dose level investigated.
The total low beam scores for all groups of treated males were slightly lower than Control, however, the individual data revealed some inter-group variability with no common trends. The total high beam score for females that received 7500 ppm were slightly higher than Control, however, there was one atypical female (No.170) which had consistently high high beam scores throughout the 1-hour testing period compared to the other females in this group. This female showed a normal pattern of lower activity during the second half of the recording period so this data is deemed to be genuine. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The microscopic examination performed after 6 weeks of exposure revealed no test item-related lesions. Seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and the integrity of the various cell types present within their stages. No cell or stage specific abnormalities were noted.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on the circulating levels of thyroxine (T4) in adult males or in offspring on Day 13 of age. Consequently, there was no requirement to measure T4 in the samples obtained from offspring on Day 4 of age or from the adult females and none of the TSH (thyroid stimulating hormone) samples required analysis.
- Reproductive function: oestrous cycle:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All females allocated to the Reproductive phase of the study showed regular 4 to 5 day estrous cycles prior to the start of treatment. Females allocated to the Toxicity phase all showed regular 4 to 5 day estrous cycles prior to treatment with the exception of one Control female with an irregular cycle. Females allocated to the Recovery phase all showed regular 4 to 5 day cycles prior to treatment with the exception of one Control female with an irregular cycle.
There was no effect of treatment on estrous cycle regularity, however, it was noted that during the treatment period a high number of Reproductive phase females were observed to be acyclic, this included four females in the Control group. One Control female and one female that received 3500 ppm were observed to have irregular cycles and one female that received 1500 ppm was observed to have extended estrus. However, given that all females mated within 1-4 days, with the exception of one Control female which mated within 5-8 days, these acyclic and irregular cycles are considered to be incidental. At termination,
all Toxicity phase females and a majority of Recovery phase females were cycling and all Reproductive phase females were in diestrus. - Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- - Pre-coital interval, mating performance and fertility were considered unaffected by treatment with Labdanum Gum, when compared to Control.
- Gestation length and gestation index were considered unaffected by treatment at any dose level. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 7 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed.
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment related clinical signs observed amongst offspring following parental dietary administration of Labdanum Gum.
- Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- There was no effect of treatment with Labdanum Gum on the mean number of implantations,
litter size, post implantation survival index, live birth index, viability index or lactation index. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no effect of treatment on offspring body weights on Day 1 of age. The overall body weight gain (Day 1 to 13 of age) of male and female offspring derived from parents that received 7500 ppm was marginally lower than Control particularly in males.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment with Labdanum Gum on the mean number of implantations, litter size, post implantation survival index, live birth index, viability index or lactation index.
- Anogenital distance (AGD):
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on ano-genital distance in the male and female offspring at any dietary concentration investigated.
- Nipple retention in male pups:
- no effects observed
- Description (incidence and severity):
- No nipples were observed in male offspring of parents treated with Labdanum Gum.
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic examination of offspring that either died prematurely or at scheduled termination on Day 13 of age did not reveal any findings that could be attributed to treatment.
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 7 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects were observed.
- Key result
- Critical effects observed:
- not specified
- Key result
- Reproductive effects observed:
- not specified
- Conclusions:
- Under the test conditions of this study, the No Observed Adverse Effect Level (NOAEL) for general systemic toxicity was the high dose (target dietary
concentration of 7500 ppm) with mean achieved doses of 322 mg/kg bw/day in males and 331 mg/kg bw/day in females. It was also concluded the NOAEL for reproductive/developmental toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 342 mg/kg bw/day during gestation and 731 mg/kg bw/day during lactation. - Executive summary:
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test conducted according to OECD Guideline 422 and in compliance with GLP, the test item was administered to groups of Crl:CD(SD) rats at dietary concentrations of 1500, 3500 and 7500 ppm. An additional subgroup was used to assess reversibility, persistence or delayed occurrence of systemic effects for 14 days post treatment. A similarly constituted control group was assigned to each phase, and received the vehicle, powdered SDS VRF1 Certified diet with corn oil, throughout the same relative treatment period.
Toxicity phase males were treated for three weeks before pairing up to necropsy after a minimum of six weeks. Toxicity phase females were treated for at least six weeks. Recovery phase males were treated for three weeks before pairing up to necropsy after a minimum of six weeks followed by a minimum 14-day recovery. Recovery phase females were treated for six weeks followed by a minimum 14-day recovery.
Reproductive phase females were treated for three weeks before pairing, then throughout pairing and gestation until Day 12 of lactation. Females were allowed to litter and rear their offspring to weaning and were killed on Day 13 of lactation (the treated diet was made available until the morning of necropsy).
The offspring received no direct administration of the test item; any exposure was in utero or via the milk. Selected F1 offspring were sampled and killed on Day 4 (not analyzed) or Day 13 of age for analysis of blood thyroid hormone levels. The remaining F1 offspring were killed on Day 13 of age.
During the study, clinical condition, detailed physical examination and arena observations, sensory reactivity, grip strength, motor activity, body weight, food consumption, water consumption (by visual assessment), ophthalmic examination, hematology (peripheral blood),
blood chemistry, urinalysis, thyroid hormone analysis, estrous cycles, pre-coital interval, mating performance, fertility, gestation length, organ weight and macroscopic pathology and histopathology investigations were undertaken. The clinical condition, litter size and survival, sex ratio, body weight, nipple counts (males only), ano-genital distance and macropathology for all offspring were also assessed.
Each diet preparation was analysed for achieved concentration and homogeneity. The mean concentrations were within -16.0% to -33.6% of the nominal concentration. The coefficient of variation values remained within 5%, with the exception of Week 1 Group 3 and Week 7
Group 3 and 4, which were 5.46%, 5.87% and 6.94%, respectively. On this study, target dietary concentrations were set in the study plan and referenced throughout the report, however, each diet preparation was analysed for achieved concentration prior to being fed to the animals.
The overall mean achieved doses for Toxicity, Recovery and Reproductive phase animals during treatment that received Labdanum Gum at target dietary concentrations of 1500, 3500 or 7500 ppm were 65, 140 and 322 mg/kg bw/day in males and 68, 155 and 331 mg/kg bw/day in females, respectively. The overall mean achieved doses for Reproductive phase females that received target dietary concentrations of 1500, 3500 or 7500 ppm were 70, 175 and 342 mg/kg bw/day and 163, 376 and 731 mg/kg bw/day during gestation and lactation respectively.
There was no effect of treatment on the circulating levels of thyroxine (T4) in adult males or in offspring on Day 13 of age.
One male that received 1500 ppm was killed for welfare reasons on Day 29 of study due to a damaged right eye. Macroscopic examination revealed a protruding and abnormal dark coloured right eye. This death was not considered to be related to treatment with Labdanum Gum. There were no test-item related signs observed during detailed physical examination and arena observation and no effects on sensory reactivity, grip strength or motor activity.
Effects on body weight performance and food consumption (comprising periods of low mean weight gain and reduced food consumption) were evident throughout the treatment period for all groups of treated Toxicity and Recovery phase males and females. Following the commencement of treatment, an initial reduction in body weight gain was evident for males that received 3500 or 7500 ppm as well as minor mean weight loss in all groups of treated females. In addition, an initial reduction in food intake was evident following the commencement of treatment for females that received 7500 ppm. These effects were considered to be related to the palatability of the test item. Thereafter, the food intake of females that received 7500 ppm remained marginally low. Overall group mean body weight gain throughout the treatment period (Days 1 to 43) was slightly low for all groups of treated males and females that received 3500 or 7500 ppm. The food intake of all groups of treated males was generally marginally lower than Control for the first three weeks of treatment (Days 1 to 22) and the food intake of females that received 1500 or 3500 ppm was generally slightly lower than or comparable to Control. Following six weeks of treatment, the terminal body weights for Toxicity phase females that received 7500 ppm were statistically significantly lower than Control.
Food intake during early gestation (Days 0 to 8) for Reproductive phase females that received 7500 ppm was marginally lower than Control but comparable to Control thereafter. Overall body weight gain throughout lactation (Days 1 to 13) was slightly lower than Control for females that received 1500 or 7500 ppm (but not at 3500 ppm) and the food intake during lactation for females that received 7500 ppm was generally marginally lower than Control.
During the recovery period, group mean body weight gain for males that previously received 7500 ppm was slightly lower than Control, however, group mean body weight gain during the recovery phase for females that previously received 7500 ppm was higher than Control.
There was no treatment-related ophthalmoscopic finding. There were no treatment-related effects on oestrous cycles, pre-coital interval, mating
performance, fertility and gestation length.
Haematological examination of the peripheral blood during Week 6 of treatment did not reveal any toxicologically significant differences from Control.
Biochemical assessment of the plasma during Week 6 of treatment revealed that creatinine levels for all groups of treated males were statistically significantly higher than Control. Following a two-week recovery period, creatinine levels for males that had previously received 7500 ppm were comparable to Control. A statistically significant decrease in urea concentration was apparent in females that received 7500 ppm. Following a two-week recovery period, urea concentration in females that had previously received 7500 ppm was comparable to Control. In addition, a statistically significant increase in phosphorus levels was apparent amongst males and females that received 7500 ppm. Following a two-week recovery period, phosphorus levels in males and females that had previously received 7500 ppm were comparable to Control. Globulin levels for females that received 7500 ppm were statistically significantly higher than Control. Following a two-week recovery period, globulin levels in females that had previously received 7500 ppm were comparable to Control.
The analysis of urine during Week 6 of treatment revealed that total creatinine output was higher than Control for males treated at 3500 or 7500 ppm, however, all values were within the HCD range and no such trend was apparent in the females. In addition, sodium concentration was higher than Control for all groups of treated females, however, all values were also within the HCD range and no such trend was apparent in the males.
Following six weeks of treatment, terminal body weights for Toxicity phase females that received 7500 ppm were statistically significantly lower than Control. Changes in organ weights consisted of a dosage related decrease in group mean body weight adjusted adrenal weights in Toxicity phase males, with statistical significance attained at 7500 ppm. Following the two-week recovery period, group mean body weight adjusted adrenal weight for males that previously received 7500 ppm were comparable to Control. Group mean body weight adjusted thymus weights were statistically significantly lower than Control in all groups of treated Toxicity phase males, however, no dose response was apparent. Following the two-week recovery period, group mean body weight adjusted thymus weights for males that previously received 7500 ppm were comparable to Control. Group mean body weight adjusted ovary weights were slightly low at 7500 ppm for the Toxicity phase females but the difference did not attain statistical significance.
Macroscopic and microscopic examination of a full range of organs/tissues from the adult males and females revealed no test-item related lesions.
There were no treatment related clinical signs observed amongst offspring following parental dietary administration of Labdanum Gum.
There was no effect of treatment with Labdanum Gum on the mean number of implantations, litter size, post implantation survival index, live birth index, viability index or lactation index. There was no effect of treatment on offspring body weights on Day 1 of age. The overall body weight gain of male and female offspring derived from parents that received 7500 ppm was marginally lower than Control. There was no effect of treatment on ano-genital distance in the male and female offspring and no nipples were seen in male offspring. There were no findings associated with treatment at macroscopic examination.
Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) for general systemic toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 322 mg/kg bw/day in males and 331 mg/kg bw/day in females.
It was also concluded the NOAEL for reproductive/developmental toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 342 mg/kg bw/day during gestation and 731 mg/kg bw/day during lactation.
This study is considered as acceptable and satisfies the requirement for toxicity to reproduction endpoint.
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 326 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Recent GLP study conducted according to OECD Guideline No 422 without any deviation (Klimisch score = 1).
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
One study was available and considered as the key study (OECD 422, Covance 2019, Rel.1). In this study, the test item was administered to groups of Crl:CD(SD) rats at dietary concentrations of 1500, 3500 and 7500 ppm. An additional subgroup was used to assess reversibility, persistence or delayed occurrence of systemic effects for 14 days post treatment. A similarly constituted control group was assigned to each phase, and received the vehicle, powdered SDS VRF1 Certified diet with corn oil, throughout the same relative treatment period.
Each diet preparation was analysed for achieved concentration and homogeneity. The mean concentrations were within -16.0% to -33.6% of the nominal concentration. The coefficient of variation values remained within 5%, with the exception of Week 1 Group 3 and Week 7
Group 3 and 4, which were 5.46%, 5.87% and 6.94%, respectively. On this study, target dietary concentrations were set in the study plan and referenced throughout the report, however, each diet preparation was analysed for achieved concentration prior to being fed to the animals.
The overall mean achieved doses for Toxicity, Recovery and Reproductive phase animals during treatment that received Labdanum Gum at target dietary concentrations of 1500, 3500 or 7500 ppm were 65, 140 and 322 mg/kg bw/day in males and 68, 155 and 331 mg/kg bw/day in females, respectively. The overall mean achieved doses for Reproductive phase females that received target dietary concentrations of 1500, 3500 or 7500 ppm were 70, 175 and 342 mg/kg bw/day and 163, 376 and 731 mg/kg bw/day during gestation and lactation respectively.
There was no effect of treatment on the circulating levels of thyroxine (T4) in adult males or in offspring on Day 13 of age.
One male that received 1500 ppm was killed for welfare reasons on Day 29 of study due to a damaged right eye. Macroscopic examination revealed a protruding and abnormal dark coloured right eye. This death was not considered to be related to treatment with Labdanum Gum. There were no test-item related signs observed during detailed physical examination and arena observation and no effects on sensory reactivity, grip strength or motor activity.
Effects on body weight performance and food consumption (comprising periods of low mean weight gain and reduced food consumption) were evident throughout the treatment period for all groups of treated Toxicity and Recovery phase males and females. Following the commencement of treatment, an initial reduction in body weight gain was evident for males that received 3500 or 7500 ppm as well as minor mean weight loss in all groups of treated females. In addition, an initial reduction in food intake was evident following the commencement of treatment for females that received 7500 ppm. These effects were considered to be related to the palatability of the test item. Thereafter, the food intake of females that received 7500 ppm remained marginally low. Overall group mean body weight gain throughout the treatment period (Days 1 to 43) was slightly low for all groups of treated males and females that received 3500 or 7500 ppm. The food intake of all groups of treated males was generally marginally lower than Control for the first three weeks of treatment (Days 1 to 22) and the food intake of females that received 1500 or 3500 ppm was generally slightly lower than or comparable to Control. Following six weeks of treatment, the terminal body weights for Toxicity phase females that received 7500 ppm were statistically significantly lower than Control.
Food intake during early gestation (Days 0 to 8) for Reproductive phase females that received 7500 ppm was marginally lower than Control but comparable to Control thereafter. Overall body weight gain throughout lactation (Days 1 to 13) was slightly lower than Control for females that received 1500 or 7500 ppm (but not at 3500 ppm) and the food intake during lactation for females that received 7500 ppm was generally marginally lower than Control.
During the recovery period, group mean body weight gain for males that previously received 7500 ppm was slightly lower than Control, however, group mean body weight gain during the recovery phase for females that previously received 7500 ppm was higher than Control.
There was no treatment-related ophthalmoscopic finding. There were no treatment-related effects on oestrous cycles, pre-coital interval, mating
performance, fertility and gestation length.
Haematological examination of the peripheral blood during Week 6 of treatment did not reveal any toxicologically significant differences from Control.
Biochemical assessment of the plasma during Week 6 of treatment revealed that creatinine levels for all groups of treated males were statistically significantly higher than Control. Following a two-week recovery period, creatinine levels for males that had previously received 7500 ppm were comparable to Control. A statistically significant decrease in urea concentration was apparent in females that received 7500 ppm. Following a two-week recovery period, urea concentration in females that had previously received 7500 ppm was comparable to Control. In addition, a statistically significant increase in phosphorus levels was apparent amongst males and females that received 7500 ppm. Following a two-week recovery period, phosphorus levels in males and females that had previously received 7500 ppm were comparable to Control. Globulin levels for females that received 7500 ppm were statistically significantly higher than Control. Following a two-week recovery period, globulin levels in females that had previously received 7500 ppm were comparable to Control.
The analysis of urine during Week 6 of treatment revealed that total creatinine output was higher than Control for males treated at 3500 or 7500 ppm, however, all values were within the HCD range and no such trend was apparent in the females. In addition, sodium concentration was higher than Control for all groups of treated females, however, all values were also within the HCD range and no such trend was apparent in the males.
Following six weeks of treatment, terminal body weights for Toxicity phase females that received 7500 ppm were statistically significantly lower than Control. Changes in organ weights consisted of a dosage related decrease in group mean body weight adjusted adrenal weights in Toxicity phase males, with statistical significance attained at 7500 ppm. Following the two-week recovery period, group mean body weight adjusted adrenal weight for males that previously received 7500 ppm were comparable to Control. Group mean body weight adjusted thymus weights were statistically significantly lower than Control in all groups of treated Toxicity phase males, however, no dose response was apparent. Following the two-week recovery period, group mean body weight adjusted thymus weights for males that previously received 7500 ppm were comparable to Control. Group mean body weight adjusted ovary weights were slightly low at 7500 ppm for the Toxicity phase females but the difference did not attain statistical significance.
Macroscopic and microscopic examination of a full range of organs/tissues from the adult males and females revealed no test-item related lesions.
There were no treatment related clinical signs observed amongst offspring following parental dietary administration of Labdanum Gum.
There was no effect of treatment with Labdanum Gum on the mean number of implantations, litter size, post implantation survival index, live birth index, viability index or lactation index. There was no effect of treatment on offspring body weights on Day 1 of age. The overall body weight gain of male and female offspring derived from parents that received 7500 ppm was marginally lower than Control. There was no effect of treatment on ano-genital distance in the male and female offspring and no nipples were seen in male offspring. There were no findings associated with treatment at macroscopic examination.
Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) for general systemic toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 322 mg/kg bw/day in males and 331 mg/kg bw/day in females.
It was also concluded the NOAEL for reproductive/developmental toxicity was the high dose (target dietary concentration of 7500 ppm) with mean achieved doses of 342 mg/kg bw/day during gestation and 731 mg/kg bw/day during lactation.
Effects on developmental toxicity
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Harmonized classification:
The substance has no harmonized classification according to the Regulation (EC) No 1272/2008 (CLP).
Self-classification:
In a recent GLP repeated dose toxicity study (OECD guideline 422), no adverse systemic toxicity changes were observed in males and females rats exposed to the registered substance. Furthermore, no effects on fertility and post-natal effects were observed. In this OECD guideline 422 study, the NOAEL was set at 7500 ppm. Therefore, the registered substance does not need to be classified for reproductive toxicity according to CLP Regulation (EC) n° 1272/2008 and UN GHS criteria.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)